Department of Neurology, IRCCS Neuromed Institute, Pozzilli, IS, Italy.
J Neural Transm (Vienna). 2013 Aug;120(8):1209-15. doi: 10.1007/s00702-013-0972-6. Epub 2013 Jan 18.
Among promising biological markers proposed for Parkinson's disease (PD) and other disorders related to Lewy bodies, plasma alpha-synuclein assay has provided conflicting results mainly owing to the various laboratory assay techniques used and protein forms assayed. In this observational and exploratory cross-sectional study, using an immunoenzymatic technique, we assayed and compared total plasma alpha-synuclein concentrations in 69 patients with PD and 110 age-matched healthy control subjects. Two previously unreported findings concerned gender. First, plasma alpha-synuclein concentrations measured in the more advanced parkinsonian disease stages decreased in men, but not in women. Second, again only in men, plasma alpha-synuclein concentration was associated with cognitive impairments, hallucinations, and sleep disorders. These findings underline the gender-related differences in parkinsonian patients and indicate plasma alpha-synuclein expression as a potential biological marker for PD progression in men.
在帕金森病（PD）和其他与路易体相关的疾病的有前途的生物标志物中，血浆α-突触核蛋白检测提供了相互矛盾的结果，主要归因于所使用的各种实验室检测技术和所检测的蛋白质形式。在这项观察性和探索性的横断面研究中，我们使用免疫酶技术检测并比较了 69 名 PD 患者和 110 名年龄匹配的健康对照者的总血浆α-突触核蛋白浓度。有两个以前未报道过的发现与性别有关。首先，在帕金森病晚期阶段测量的血浆α-突触核蛋白浓度在男性中降低，但在女性中没有降低。其次，仅在男性中，血浆α-突触核蛋白浓度与认知障碍、幻觉和睡眠障碍有关。这些发现强调了帕金森病患者中的性别差异，并表明血浆α-突触核蛋白表达是男性 PD 进展的潜在生物学标志物。
